Luo Pei, Yang Qing, Cong Le-Le, Wang Xiao-Feng, Li Yu-Sheng, Zhong Xiao-Ming, Xie Ru-Ting, Jia Cheng-You, Yang Hui-Qiong, Li Wen-Ping, Cong Xian-Ling, Xia Qing, Fu Da, Zeng Qing-Hua, Ma Yu-Shui
College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, P.R. China.
Department of Neurology, China Japan Union Hospital, Jilin University, Changchun, Jilin 130031, P.R. China.
Mol Med Rep. 2017 Jul;16(1):238-246. doi: 10.3892/mmr.2017.6595. Epub 2017 May 17.
Previous studies have suggested that dysregulation of microRNA (miR) -124a is associated with various types of human cancer. However, there are few studies reporting the level of miR‑124a expression in non‑small cell lung cancer (NSCLC). The present study investigated the association between miR‑124a and NSCLC by analyzing the differential expression of miR‑124a in NSCLC using the GEO database, as well as subsequently performing reverse transcription‑quantitative polymerase chain reaction analysis on 160 NSCLC biopsies, 32 of which were paired with adjacent normal tissues. The results indicated that mir‑124a expression levels were decreased in NSCLC tumor biopsies compared with adjacent normal tissues. The overall survival (OS) in patients with a high expression of miR‑124a was prolonged relative to patients with low expression of miR‑124a. The expression levels of miR‑124a were associated with clinical characteristics, including lymph‑node metastasis, tumor differentiation, tumor node metastasis (TNM) stage and diameter. Frequently, lymph‑node metastasis, TNM stage, diameter and lack of chemotherapy have been associated with a worse prognosis in patients. In addition, the present study identified that high expression of miR‑124awith chemotherapy may increase OS. In conclusion, the current study demonstrated that miR‑124a was downregulated in NSCLC, and miR‑124a was a potential prognostic tumor biomarker response to chemotherapy.
以往研究表明，微小RNA（miR）-124a失调与多种人类癌症相关。然而，鲜有研究报道非小细胞肺癌（NSCLC）中miR-124a的表达水平。本研究通过使用GEO数据库分析NSCLC中miR-124a的差异表达，以及随后对160例NSCLC活检组织（其中32例与癌旁正常组织配对）进行逆转录-定量聚合酶链反应分析，探讨了miR-124a与NSCLC之间的关联。结果表明，与癌旁正常组织相比，NSCLC肿瘤活检组织中mir-124a表达水平降低。miR-124a高表达患者的总生存期（OS）相对于miR-124a低表达患者延长。miR-124a的表达水平与临床特征相关，包括淋巴结转移、肿瘤分化、肿瘤-淋巴结-转移（TNM）分期和直径。通常，淋巴结转移、TNM分期、直径以及未接受化疗与患者预后较差相关。此外，本研究发现miR-124a高表达联合化疗可能会延长OS。总之，本研究表明miR-124a在NSCLC中表达下调，且miR-124a是一种潜在的化疗预后肿瘤生物标志物。
